Bio-AMD Inc. (fka BIAD)

[Strukture]

**BIAD** ISNT JUST SOME OTHER OTC PLAY - THIS IS A TOP TIERED QB STOCK WITH MASSIVE POTENTIAL AND HUGE BACKING BY A BILLION MARKET CAP COMPANY.. THE DD IS SUPERLATIVE - PLEASE READ!

http://microcapresearch.com/bio-amd-inc/

45 million OS -- no dilution in 2 years from fillings
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10306932

Last news IS BEYOND impressive - they have a partnership with SYSMEX - billion market cap bio company trading in Tokyo stock exchange

http://www.otcmarkets.com/stock/BIAD/news
look at SYSMEX growth over last 10 years http://bloomberg.com/research/stocks/charts/charts.asp?ticker=6869:JP

Bio-AMD, Inc. Agreement with Sysmex & General Update
http://finance.yahoo.com/news/bio-amd-inc-agreement-sysmex-134500850.html

LONDON, ENGLAND / ACCESSWIRE / January 27, 2015 / Bio-AMD, Inc. and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD", "We" or the "Company") (BIAD) provides an update on the Company's plans for 2015.

On December 17, 2014 Bio Alternative Medical Devices Ltd. entered into a Master Agreement with Sysmex Corporation regarding the prospective development of the Company's coagulation diagnostic system ("COAG"). An expense contribution payment of approximately $1,000,000 was received from Sysmex on January 20, 2015.
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, China and Asia Pacific and employs more than 4,500 employees worldwide. Sysmex is traded on the Tokyo Stock Exchange and has a market capitalization of approximately 1.1 trillion Yen, or 9.1 billion U.S. Dollars.
During 2015 the Company intends to continue the development of its novel Magnetic Immunoassay Detection System ("MIDS") technology. MIDS is designed as a fully quantitative point of care diagnostic device comprising a disposable strip and hand held reader which we believe will provide rapid near-patient testing with laboratory accuracy across a wide range of tests. Initially we intend to focus development of the technology into the detection of cardiac markers. The Company believes that the recent grant funding award from the UK's innovation agency for a proof of market study endorses the potential for MIDS. Further grant funding applications will be made as opportunity arises. The Company believes that the potential for MIDS will be recognised by prospective global partners as the MIDS technology is advanced through its development program which is expected to de-risk the project and enhance its attractiveness to third parties.

Also during 2015 the Company also intends to explore further options for its developed digital lateral flow strip based detection system ("DSR") technology, including application to molecular diagnostics tests.

Tom Barr, CEO of Bio-AMD, Inc. commented, "The Company is delighted that its COAG technology has the contracted interest of such a prestigious partner in the haemostasis space. It is a step-change event that proves that the Company is capable of engaging with a partner with the international presence necessary to bring its novel technology to a global market. We now have a platform from which to further our growth strategy, with the progression of our MIDS technology project being a primary objective for this year."

Dr. Nasser Djennati, MD of Bio Alternative Medical Devices Ltd. Commented, "We are excited at the prospects for our COAG system and to be working closely with Sysmex. Our growth strategy aims to expand our pipeline technologies for further application into the growing point of care diagnostic space."